New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.
Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.
ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.
ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.
ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.
ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.
ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.
The observational study found that longer duration of disease conferred a 32% greater risk of obesity and that nonatopic asthma carried at 47% greater risk.